{"entity":{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","aka":[],"tldr":"Instead of making cell therapy from each patient's own cells in a factory, inject a particle that reprograms immune cells inside the body, made in bulk, so a dose costs thousands rather than hundreds of thousands.","summary":"Autologous CAR-T costs hundreds of thousands of dollars and weeks of manufacturing per patient, restricting it to a small fraction of eligible patients in rich countries. In vivo CAR generation with lipid nanoparticles or targeted lentiviral vectors (Umoja, Interius, Orna and others) has entered the clinic in B-cell malignancies. The proposal is a coordinated programme to develop an in vivo CD19 or BCMA product with a manufacturing process and cost-of-goods target under $5,000 per dose, licensed for distribution through generic-style manufacturers in middle-income countries, with regulatory pathways agreed in advance.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":["idea-in-vivo-car-solid"],"cancers":["dlbcl","multiple-myeloma"],"sections":[],"technologies":["in-vivo-car-t","car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":["umoja-biopharma","interius","orna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access","b-drug-pricing"],"keyPapers":["paper-hernandez-jama-oncol","paper-bcma-multiple-myeloma-leukemia-2020","paper-cd19-multiple-myeloma-lancet-haematol-2019","paper-cd19-multiple-myeloma-blood-2020"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An off-the-shelf in vivo CAR product achieves complete remission rates within 15 percentage points of autologous CAR-T in relapsed B-cell malignancies at less than a tenth of the delivered cost, enabling treatment of ten times as many patients.","rationale":"The cost of autologous therapy is in logistics and bespoke manufacturing, not in the biology; nucleic acid-lipid manufacturing scales like a vaccine.","test":"Phase 2 in relapsed large B-cell lymphoma with pre-specified cost-of-goods reporting and a parallel technology transfer to a manufacturer in India or Brazil.","maturity":"preclinical-evidence","actor":"industry","cost":"large","horizonYears":7},"route":"/ideas/idea-moon-in-vivo-cart-generic-price/","neighbours":{"idea":[{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/"},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/"},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/"},{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/"},{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/"},{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}